VAXXILON
Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines. Headquartered near Basel, Switzerland with research labs in Berlin, the Vaxxilon team is advancing several vaccine candidates for the prevention of major infectious diseases.
VAXXILON
Industry:
Biotechnology Pharmaceutical
Founded:
2015-01-01
Address:
Reinach, Aargau, Switzerland
Country:
Switzerland
Website Url:
http://www.vaxxilon.com
Total Employee:
1+
Status:
Active
Total Funding:
1.4 M USD
Technology used in webpage:
SPF ReCAPTCHA Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Gravity Forms CSC Global DNS CSC
Similar Organizations
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Zhiyi Pharmaceutics
Zhiyi Pharmaceutics focuses on the research and development of second-generation probiotics and Live Biotherapeutics.
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Vaxxilon
More informations about "Vaxxilon"
The vaccines company - Max Planck Society
Jun 29, 2015 · Vaxxilon, a company jointly founded by the Max Planck Society and the Swiss firm Actelion Ltd, will carry out research and development of these carbohydrate-based vaccines and bring them to market. The synthetic …See details»
Vaxxilon - Crunchbase Company Profile & Funding
Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines. Headquartered near Basel, Switzerland with research labs in Berlin, the Vaxxilon …See details»
A synthesis of science and industry
Jul 7, 2015 · Vaxxilon is a start-up company founded by the Max Planck Society and the Swiss biotech firm Actelion, which aims to bring synthetic, polysaccharide-based vaccines to market. The company’s research division …See details»
Media release - Idorsia
Jul 23, 2020 · Vaxxilon Deutschland GmbH – now a 100% subsidiary of Idorsia – is specialized in synthetic carbohydrate vaccines to prevent infections. Idorsia is now advancing vaccines …See details»
Idorsia Governance Report 2020
Vaxxilon Ltd – a majority-owned subsidiary of Idorsia Ltd, based in Reinach/BL, Switzerland – was merged into Idorsia Pharmaceuticals Ltd as of June 26, 2020, and removed from the …See details»
Idorsia Governance Report 2019
Idorsia Pharmaceuticals US Inc. – a 100% subsidiary of Idorsia Ltd, based in New Jersey, US – performs clinical development on behalf of the Group. Vaxxilon Ltd – a majority-owned …See details»
Vaxxilon Company Profile 2024: Valuation, Investors, Acquisition ...
Developer of innovative synthetic carbohydrate vaccines designed to offer novel vaccines against major infectious diseases. The company's team is advancing several vaccine candidates using …See details»
CARB-X funds Vaxxilon AG to develop a new vaccine to prevent …
Aug 20, 2019 · Arne von Bonin, CSO and Head of Immunology at Vaxxilon, said: “CARB-X’s award will support the development of VXN-319, a semi-synthetic conjugate vaccine targeting …See details»
Taming vaccines with chemistry | Business | Chemistry …
Vaxxilon was set up in June 2015 by German chemist Peter Seeberger, director of the Max Planck Institute for Colloids and Surfaces in Potsdam, with backing from the Max Planck Society and Swiss ...See details»
Vaxxilon - Funding, Financials, Valuation & Investors - Crunchbase
Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines.See details»
Vaxxilon named “Science Start-Up of the Year 2016”
Nov 17, 2016 · The company nominated by Max Planck Innovation, Vaxxilon, emerged as the winner and was proclaimed the “Science Start-Up of the Year 2016” for its development of a carbohydrate-based agent. The new agent …See details»
CARB-X funds Vaxxilon AG to Develop a New Vaccine to Prevent …
CARB-X, a global partnership led by Boston University, is awarding Vaxxilon AG of Reinach, Switzerland, up to $1.4 million in non-dilutive funding with the possibility of $3.1 million more if …See details»
Arne von Bonin, PhD Vaxxilon - PDA
Before joining Vaxxilon in 2016, Arne was the CSO and a board member of AFFiRiS, Vienna and worked from 2003 until 2012 in different R&D related functions at Bayer Healthcare AG (before …See details»
Tom Monroe - ERC
Tom Monroe serves as the CEO of Vaxxilon AG which was established to develop synthetic carbohydrate vaccines. Prior to co-founding Vaxxilon, he held multiple positions over twenty …See details»
Synthetic carbohydrate wards off pneumococcal infections
Mar 22, 2018 · To this end they are collaborating with the start-up Vaxxilon AG, which was established by the Max Planck Society on the initiative of Peter Seeberger and the Swiss …See details»
Vaxxilon awarded CARB-X grant to advance novel prophylactic …
Aug 20, 2019 · Vaxxilon, a privately held company working on synthetic vaccines, has been awarded a grant of up to USD 1.4 million from CARB-X, with the possibility of USD 3.1 million …See details»
A sugar-based molecule could act as a vaccine against C. difficile ...
May 11, 2016 · In order to progress from research results to actual use in patients, the scientists at the Max Planck Institute of Colloids and Interfaces in Potsdam are working with Vaxxilon AG …See details»
Development of an Efficacious, Semisynthetic Glycoconjugate …
Mar 3, 2018 · Here, we developed an efficacious semisynthetic ST1 glycoconjugate vaccine candidate. A panel of synthetic oligosaccharides served to reveal a critical role of the rare …See details»
VXN 319 - AdisInsight - Springer
VXN 319 is a semi-synthetic multivalent, glycoconjugate vaccine, being developed by Idorsia Pharmaceuticals (previously Vaxxilon) for the prevention ofSee details»
A semisynthetic Streptococcus pneumoniae serotype 8 ... - Science
Mar 8, 2017 · P.H.S., C.L.P., and S.G.P. have a significant financial interest in Vaxxilon AG, a company that is developing vaccines based on synthetic oligosaccharide antigens and has …See details»